Patents
US 9040591 B2: Methods and compositions comprising at least one α3 βA4 nAChR antagonist or pharmaceutically acceptable salt thereof
- Granted
- 2015-05-26
- Filed
- 2012-07-19 application 13553453
- Type
- Utility · 12 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one α3 β4 nAChR antagonist and formulations comprising at least one α3 β4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.
Source: PVGPATDIS, file of 2026-04-10 (ipg150526.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| AGI Therapeutics Public Limited Company 1 patents | Foreign company or organization | Dublin, IE | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| John Devane | Roscommon, IE | 16 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K45/06 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P1/00 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2023-10-06 | Release of security interest Release of security interest | CITIBANK, N.A. signed 2023-10-06 | HORIZON THERAPEUTICS IRELAND DAC (SUCCESSOR IN INTEREST TO HORIZON PHARMA SERVICES LIMITED) DUBLIN 2 HORIZON THERAPEUTICS IRELAND DAC (FKA HORIZON PHARMA IRELAND LIMITED) DUBLIN 2 HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) DEERFIELD, IL HZNP LIMITED DUBLIN 2 | 65153/953 | PASDL, file of 2026-10-15 |
| 2018-08-14 | Assignment Assignment of assignor's interest | HORIZON PHARMA SERVICES LIMITED signed 2018-08-14 | HORIZON PHARMA IRELAND LIMITED DUBLIN 4 | 46803/950 | ECORSEXC, file of 2026-09-25 |
| 2015-08-12 | Name change Change of name | AGI THERAPEUTICS LIMITED signed 2014-10-03 | HORIZON PHARMA SERVICES LIMITED DUBLIN | 36309/553 | ECORSEXC, file of 2026-09-25 |
| 2015-05-07 | Security interest Security interest Security interest | HORIZON PHARMA SERVICES LIMITED (FORMERLY AGI THERAPEUTICS LIMITED) signed 2015-05-07 | CITIBANK, N.A. NEW YORK, NY | 35590/889 | ECORSEXC, file of 2026-09-25 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.